CD86 and neoplasm: In the tumor, XCR1 detection was also decreased in mice treated with the high dose of the XCR1Ab-IFNL53A fusion (10 mg/kg) compared to the isotype control (Figures 4D, E), which correlated with a significant gain in IFN activity in cDC1s, based on greater PD-L1 and CD86 expression (Figure 4F).